Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00034957
First received: May 2, 2002
Last updated: February 14, 2012
Last verified: February 2012
  Purpose

The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Drug: Investigational drug
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Pfizer:

Study Completion Date: October 2002
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy. Patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. Any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria: Any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known HIV-positive or AIDS-related illness.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034957

Locations
United States, California
Research Center
Berkeley, California, United States, 94704
Research Center
Greenbrae, California, United States, 94904-2007
Research Center
Los Angeles, California, United States, 90048
Research Center
Rancho Mirage, California, United States, 92270
United States, Illinois
Research Center
Chicago, Illinois, United States, 60637-1463
United States, Kentucky
Research Center
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Research Center
West Boylston, Massachusetts, United States, 01583
United States, Michigan
Research Center
Ann Arbor, Michigan, United States, 48109
United States, New Hampshire
Research Center
Lebanon, New Hampshire, United States, 03756
United States, Tennessee
Research Center
Nashville, Tennessee, United States, 37232-6868
United States, Texas
Research Center
Arlington, Texas, United States, 76012
Research Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Pfizer
  More Information

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00034957     History of Changes
Other Study ID Numbers: 196-ONC-0100-005
Study First Received: May 2, 2002
Last Updated: February 14, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Pharmacia

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 14, 2014